Browse the evidence

There is no single mode of physical activity that is superior for weight loss or prevention of weight gain.

Advise clients that various forms of physical activity can be effective for weight management, and they should choose what they enjoy.

In psoriasis, 4 of 5 clinical studies demonstrated significant improvements in Psoriasis Area Severity Index and weight/body mass index.

GLP-1 receptor agonists may significantly improve psoriasis severity and contribute to weight loss.

The diet beneficially altered microbiota-derived plasma metabolites implicated in chronic non-communicable diseases.

Practitioners may consider the impact of dietary choices on metabolites that influence chronic disease risk.

Elevated body mass index and weight gain are associated with increased risk of postmenopausal, hormone receptor-positive breast cancer.

Practitioners should consider BMI and weight gain as significant risk factors for breast cancer in postmenopausal women.

The odds of discontinuation of glucose-lowering medications at year 1 differed by bMVPA timing, with the afternoon group having the highest odds (odds ratio 2.13).

Understanding the timing of physical activity may help in managing medication strategies for diabetes patients.

Non-alcoholic fatty liver disease (NAFLD) increases the risk of incident type 2 diabetes (T2D).

Practitioners should monitor T2D risk in patients with NAFLD.

Tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 mmHg for 5 mg, -5.34 mmHg for 10 mg, and -5.77 mmHg for 15 mg.

Tirzepatide may be an effective treatment for reducing systolic blood pressure in patients.

Tirzepatide treatment resulted in significant decreases in total cholesterol levels: median -3.76% for 5 mg, -4.63% for 10 mg, and -5.93% for 15 mg.

Tirzepatide may help in managing cholesterol levels in patients.

Tirzepatide treatment led to increased HDL cholesterol levels and decreased LDL cholesterol and triglyceride levels.

Tirzepatide may improve overall lipid profiles in patients.

Semaglutide improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) by +7.6 points in women and +7.5 points in men.

Semaglutide can be considered effective for improving heart failure symptoms in both men and women.

Fewer serious adverse events were reported with semaglutide compared to placebo.

Semaglutide may be a safer option for patients compared to placebo.

Low-grade systemic inflammation is linked to hypercholesterolemia and obesity.

Addressing systemic inflammation may be crucial in managing hypercholesterolemia and obesity.

Resistance training (RT) to set failure is likely not superior to non-failure RT for inducing muscle hypertrophy.

Practitioners may consider non-failure RT as effective for muscle hypertrophy.

RT performed to set failure likely exacerbates neuromuscular fatigue, muscle damage, and perceived discomfort compared to non-failure RT.

Practitioners should be cautious of the increased fatigue and discomfort associated with set failure training.

Regular physical activity boosts host immunity and facilitates a more diverse gut microbiome.

Encouraging regular physical activity can enhance immune function and gut health.

Nonelderly males with overweight and obesity experience a reduction in skeletal muscle mass of about 2 to 2.5 kg per 10-kg weight loss during voluntary caloric restriction.

Practitioners should be aware that caloric restriction can lead to significant muscle loss in males, which may need to be addressed in weight loss programs.

Nonelderly females with overweight and obesity experience a reduction in skeletal muscle mass of about 1 to 1.5 kg per 10-kg weight loss during voluntary caloric restriction.

Practitioners should be aware that caloric restriction can lead to significant muscle loss in females, which may need to be addressed in weight loss programs.

Model predictions of relative skeletal muscle changes with caloric restriction were validated in longitudinal studies.

The validation of these models can help practitioners predict muscle loss during caloric restriction more accurately.

Patients treated with semaglutide 2.4 mg had lower rates of all-cause death compared to placebo (HR: 0.81; 95% CI: 0.71-0.93).

Semaglutide may be an effective treatment for reducing overall mortality in patients with cardiovascular disease.

The study suggests reassessing the preoperative withholding guidelines for GLP-1 receptor agonists.

Healthcare providers may need to update their protocols regarding GLP-1 RA use before surgery.

Tirzepatide provides better value for money than semaglutide for weight reduction.

Healthcare providers may prefer prescribing tirzepatide over semaglutide for weight management.

Tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduces Obstructive Sleep Apnea severity (AHI) and improves cardiometabolic biomarkers in patients with moderate-to-severe OSA and obesity, leading to FDA approval for this indication.

If you have moderate-to-severe sleep apnea and obesity, ask your doctor about tirzepatide. It is an FDA-approved treatment that reduces breathing interruptions during sleep and improves heart health markers. It requires weekly injections and lifestyle counseling, but offers a viable alternative or adjunct to CPAP for those struggling with adherence or residual symptoms.

Patients treated with GLP-1 RAs experienced a lower occurrence of sight-threatening complications, including blindness (HR, 0.77; 95% CI, 0.73-0.82).

GLP-1 RAs may help reduce the risk of severe ocular complications in T2D patients.

Active GLP-1 RA prescription was associated with a significant reduction in postoperative wound dehiscence (RR: 0.711; P = 0.001).

GLP-1 RA may be beneficial in reducing wound complications post-surgery.